IB Net Payout Yields Model

Novavax: Dead Cat Bounce

 

  • Novavax, Inc. bounced on hype while the prospects from the business continued to dim with the demand for Covid vaccines.
  • The small biotech has major doubts about the financial picture of the company considering the massive operating expense structure built up to produce Covid vaccines.
  • Novavax stock remains a Sell due to like further dilution ahead and no logical path to profits.
  • This idea was discussed in more depth with members of my private investing community, Out Fox The Street. Learn More » 
Following a going concern proclamation from the company, Novavax, Inc. (NASDAQ:NVAX) had bounced over 50% of the lows to over $9. The biotech faces a problematic year as demand for Covid boosters dries up and the company has a

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Comments

Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

C3.ai: Trough Quarter

Ouster: New Day